Giampaolo Bianchini

Featured in: Favicon

nature.com Favicon

healio.com Favicon

aacrjournals.org Favicon

ejcancer.com Favicon

oncoinfo.it Favicon

cancerres.aacrjournals.org

Articles

Publisher Correction: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial - Nature Medicine

Dec 9, 2024 | nature.com | Nadia Harbeck |Eva Ciruelos |Roisin M. Connolly |Sally Baron-Hay |Giampaolo Bianchini |Hans Wildiers | +1 more

Correction to: Nature Medicine https://doi.org/10.1038/s41591-024-03261-7, published online 13 September 2024. In the version of this article initially published, members of the DESTINY-Breast12 study group were not included by the journal in the full text. In Table 1, under the “Prior CNS therapies n (%)” section, seven rows have been added, in addition to the original CNS radiotherapy, WBRT and SRS rows.
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial - Nature Medicine

Sep 13, 2024 | nature.com | Nadia Harbeck |Eva Ciruelos |Roisin M. Connolly |Sally Baron-Hay |Giampaolo Bianchini |Hans Wildiers | +1 more

AbstractTrastuzumab deruxtecan (T-DXd) intracranial activity has been observed in small or retrospective patient cohorts with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (mBC) and stable or active (untreated/previously treated and progressing) brain metastases (BMs).

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →